ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Early clinical predictors of macrolide-resistant Mycoplasma pneumoniae pneumonia in hospitalized children during the 2024 outbreak in South Korea.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAfter the COVID-19 emergency phase, Mycoplasma pneumoniae (MP) infections surged globally, heightening concerns over macrolide-resistant M. pneumoniae (MRMP), especially in children. Early detection of MRMP is crucial for reducing morbidity and optimizing antimicrobial use, but developing reliable prediction models remains challenging.
methodsThis retrospective study evaluated 458 hospitalized children with PCR-confirmed MP pneumonia during the 2024 outbreak at a South Korean university hospital. We compared demographic, clinical, laboratory, radiographic, and treatment data between macrolide-sensitive (MS) and -resistant groups. Multivariable logistic regression and ROC analyses identified independent predictors of resistance and developed a risk model.
resultsThe prevalence of MRMP was profoundly high at 83.8%. Compared with MS infections, MRMP was associated with older age, higher inflammatory markers, lower MP PCR cycle threshold (Ct) values, and more pulmonary complications. Multivariable analysis identified elevated erythrocyte sedimentation rate (ESR) and lower PCR Ct as robust, independent predictors of macrolide resistance. Integrating the PCR Ct value into a baseline clinical model significantly improved prediction accuracy, increasing the area under the curve (AUC) from 0.659 to 0.806. Chest radiographic findings provided negligible incremental diagnostic value (AUC 0.808).
conclusionsMRMP is highly prevalent among hospitalized children during post-emergency outbreaks in East Asia. Incorporating admission PCR Ct values and ESR into early clinical assessments substantially improves prediction of macrolide resistance, enabling timely, targeted escalation to second-line therapies.
Indexed as
Identifiers
42507274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.